Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1984 4
1985 3
1986 5
1987 1
1988 7
1989 10
1990 4
1991 8
1992 6
1993 8
1994 6
1995 7
1996 8
1997 11
1998 8
1999 7
2000 7
2001 9
2002 8
2003 12
2004 15
2005 7
2006 13
2007 8
2008 8
2009 11
2010 14
2011 18
2012 12
2013 19
2014 12
2015 10
2016 12
2017 13
2018 16
2019 10
2020 10
2021 6
2022 14
2023 12
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

355 results

Results by year

Filters applied: . Clear all
Page 1
Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure.
Wachsmann TLA, Wouters AK, Remst DFG, Hagedoorn RS, Meeuwsen MH, van Diest E, Leusen J, Kuball J, Falkenburg JHF, Heemskerk MHM. Wachsmann TLA, et al. Among authors: falkenburg jhf. Oncoimmunology. 2022 Feb 1;11(1):2033528. doi: 10.1080/2162402X.2022.2033528. eCollection 2022. Oncoimmunology. 2022. PMID: 35127255 Free PMC article.
PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer.
van Amerongen RA, Tuit S, Wouters AK, van de Meent M, Siekman SL, Meeuwsen MH, Wachsmann TLA, Remst DFG, Hagedoorn RS, van der Steen DM, de Ru AH, Verdegaal EME, van Veelen PA, Falkenburg JHF, Heemskerk MHM. van Amerongen RA, et al. Among authors: falkenburg jhf. Front Immunol. 2023 Mar 21;14:1121973. doi: 10.3389/fimmu.2023.1121973. eCollection 2023. Front Immunol. 2023. PMID: 37026005 Free PMC article.
What Defines a Good Tumour Antigen?
Morris EC, Falkenburg JHF. Morris EC, et al. Among authors: falkenburg jhf. 2022 Feb 7. In: Kröger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H, editors. The EBMT/EHA CAR-T Cell Handbook [Internet]. Cham (CH): Springer; 2022. Chapter 3. 2022 Feb 7. In: Kröger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H, editors. The EBMT/EHA CAR-T Cell Handbook [Internet]. Cham (CH): Springer; 2022. Chapter 3. PMID: 36122071 Free Books & Documents. Review.
Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain.
Meeuwsen MH, Wouters AK, Wachsmann TLA, Hagedoorn RS, Kester MGD, Remst DFG, van der Steen DM, de Ru AH, van Hees EP, Kremer M, Griffioen M, van Veelen PA, Falkenburg JHF, Heemskerk MHM. Meeuwsen MH, et al. Among authors: falkenburg jhf. J Hematol Oncol. 2023 Feb 27;16(1):16. doi: 10.1186/s13045-023-01408-6. J Hematol Oncol. 2023. PMID: 36850001 Free PMC article.
VISTA Expression on Cancer-Associated Endothelium Selectively Prevents T-cell Extravasation.
Luk SJ, Schoppmeyer R, Ijsselsteijn ME, Somarakis A, Acem I, Remst DFG, Cox DT, van Bergen CAM, Briaire-de Bruijn I, Grönloh MLB, van der Meer WJ, Hawinkels LJAC, Koning RI, Bos E, Bovée JVMG, de Miranda NFCC, Szuhai K, van Buul JD, Falkenburg JHF, Heemskerk MHM. Luk SJ, et al. Among authors: falkenburg jhf. Cancer Immunol Res. 2023 Nov 1;11(11):1480-1492. doi: 10.1158/2326-6066.CIR-22-0759. Cancer Immunol Res. 2023. PMID: 37695550
Graft versus tumor effects and why people relapse.
Falkenburg JHF, Jedema I. Falkenburg JHF, et al. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):693-698. doi: 10.1182/asheducation-2017.1.693. Hematology Am Soc Hematol Educ Program. 2017. PMID: 29222323 Free PMC article. Review.
Identification of a tumor-specific allo-HLA-restricted γδTCR.
Kierkels GJJ, Scheper W, Meringa AD, Johanna I, Beringer DX, Janssen A, Schiffler M, Aarts-Riemens T, Kramer L, Straetemans T, Heijhuurs S, Leusen JHW, San José E, Fuchs K, Griffioen M, Falkenburg JH, Bongiovanni L, de Bruin A, Vargas-Diaz D, Altelaar M, Heck AJR, Shultz LD, Ishikawa F, Nishimura MI, Sebestyén Z, Kuball J. Kierkels GJJ, et al. Among authors: falkenburg jh. Blood Adv. 2019 Oct 8;3(19):2870-2882. doi: 10.1182/bloodadvances.2019032409. Blood Adv. 2019. PMID: 31585951 Free PMC article.
Human iPSC-derived preclinical models to identify toxicity of tumor-specific T cells with clinical potential.
van Amerongen RA, Morton LT, Chaudhari UG, Remst DFG, Hagedoorn RS, van den Berg CW, Freund C, Falkenburg JHF, Heemskerk MHM. van Amerongen RA, et al. Among authors: falkenburg jhf. Mol Ther Methods Clin Dev. 2023 Jan 20;28:249-261. doi: 10.1016/j.omtm.2023.01.005. eCollection 2023 Mar 9. Mol Ther Methods Clin Dev. 2023. PMID: 36816758 Free PMC article.
The biological activities of interleukin-1.
Fibbe WE, Schaafsma MR, Falkenburg JH, Willemze R. Fibbe WE, et al. Among authors: falkenburg jh. Blut. 1989 Aug;59(2):147-56. doi: 10.1007/BF00320059. Blut. 1989. PMID: 2527574 Review.
355 results